{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:10:40Z","timestamp":1789175440544,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1181"],"award-info":[{"award-number":["CRC1181"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1483"],"award-info":[{"award-number":["CRC1483"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR2886"],"award-info":[{"award-number":["FOR2886"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jbspin.2023.105578","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T20:44:49Z","timestamp":1681764289000},"page":"105578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis"],"prefix":"10.1016","volume":"90","author":[{"given":"Melek Yalcin","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105578_bib0320","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2023.105578_bib0325","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0330","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105578_bib0335","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0167-5699(98)01353-X","article-title":"HIV infection: how effective is drug combination treatment?","volume":"19","author":"Grossman","year":"1998","journal-title":"Immunol Today"},{"key":"10.1016\/j.jbspin.2023.105578_bib0340","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105578_bib0345","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial","volume":"46","author":"O\u2019Dell","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0350","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0355","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105578_bib0360","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105578_bib0370","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/ard.2007.072447","article-title":"The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice","volume":"66","author":"Kievit","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0375","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice","volume":"71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0380","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0395","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712590903379494","article-title":"Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-\u03b1 antagonists","volume":"9","author":"Isaacs","year":"2009","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.jbspin.2023.105578_bib0400","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/keq224","article-title":"Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression","volume":"49","author":"Aerts","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105578_bib0405","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0410","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jbspin.2023.105578_bib0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor \u03b1 and interleukin-17 as a therapeutic opportunity in rheumatoid\u00a0arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0420","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0425","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0430","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0435","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/ken491","article-title":"Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis","volume":"48","author":"Blank","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105578_bib0440","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3899\/jrheum.090160","article-title":"Severe refractory rheumatoid arthritis successfully treated with combination rituximab and antitumor necrosis factor-\u03b1-blocking agents","volume":"36","author":"Koumakis","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0445","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105578_bib0450","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.120924","article-title":"Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study","volume":"40","author":"Rigby","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0455","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0460","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17a, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0465","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105578_bib0470","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0475","series-title":"Seminars in arthritis and rheumatism","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","author":"Boleto","year":"2019"},{"key":"10.1016\/j.jbspin.2023.105578_bib0480","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2023.105578_bib0485","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2023.105578_bib0495","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0500","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0510","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jbspin.2023.105578_bib0520","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0525","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jbspin.2023.105578_bib0530","first-page":"394","article-title":"Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report","volume":"18","author":"Rathod","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0535","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1111\/ajd.13752","article-title":"Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient","volume":"63","author":"Hanna","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0540","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-222415","article-title":"Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0545","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.100726","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","volume":"38","author":"Record","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0550","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case series on patients on tofacitinib in combination with a biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0555","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5152\/eurjrheum.2018.17188","article-title":"Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: a novel approach","volume":"6","author":"Nisar","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0560","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1111\/ced.14000","article-title":"Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis","volume":"44","author":"Sacchelli","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0565","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.jbspin.2023.105578_bib0570","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.15193","article-title":"Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue","volume":"47","author":"Takamura","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0575","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/jocd.14367","article-title":"Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis","volume":"21","author":"Zimmer","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0580","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1097\/RHU.0000000000001767","article-title":"Combination therapy with tofacitinib and IL-12\/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: a case series","volume":"28","author":"Shurey","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105578_bib0585","doi-asserted-by":"crossref","first-page":"m2288","DOI":"10.1136\/bmj.m2288","article-title":"Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data","volume":"370","author":"Janke","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2023.105578_bib0590","doi-asserted-by":"crossref","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105578_bib0595","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/archinternmed.2010.150","article-title":"Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus","volume":"170","author":"Timbie","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0600","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1475-6773.2009.01075.x","article-title":"Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes","volume":"45","author":"Timbie","year":"2010","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jbspin.2023.105578_bib0605","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1016\/S2589-7500(21)00130-8","article-title":"Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study","volume":"3","author":"Yebyo","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jbspin.2023.105578_bib0610","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105578_bib0615","doi-asserted-by":"crossref","first-page":"2455e5","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jbspin.2023.105578_bib0620","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2023.105578_bib0625","doi-asserted-by":"crossref","first-page":"1678e13","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jbspin.2023.105578_bib0630","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X2300057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X2300057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:31:31Z","timestamp":1761150691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X2300057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1297319X2300057X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105578","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105578"}}